Jelena P Berglund1, Nicole Szczepanski2, Anusha Penumarti2, Ayeshia Beavers2, Janelle Kesselring2, Kelly Orgel2, Bruce Burnett1, A Wesley Burks2, Michael Kulis3. 1. Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC. 2. Department of Pediatrics, Division of Allergy, Immunology, and Rheumatology, University of North Carolina at Chapel Hill, Chapel Hill, NC. 3. Department of Pediatrics, Division of Allergy, Immunology, and Rheumatology, University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address: mike.kulis@unc.edu.
Abstract
BACKGROUND: Oral immunotherapy (OIT) is an investigational therapeutic approach for the treatment of food allergies. Characterization of the drug product used in oral immunotherapy trials for peanut allergy has not been reported. OBJECTIVE: To quantify relative amounts of the major peanut allergens and microbial load present in peanut flour used in OIT trials and assess whether these parameters change over a 12-month period. We also anticipate that this report will serve as a guide for investigators seeking to conduct OIT trials under Food and Drug Administration-approved Investigational New Drug applications. METHODS: Densitometric scanning of Ara h 1 and Ara h 2 resolved on SDS-PAGE gels was used to assess allergen content in peanut flour extracts. Microbial testing was conducted on peanut flour under US Pharmacopeia guidelines for the presence of Escherichia coli, salmonella, yeast, mold, and total aerobic bacteria. In addition, aflatoxin was quantified in peanut flour. Reported results were obtained from 4 unique lots of peanut flour. RESULTS: Relative amounts of the major peanut allergens were similar between different lots of peanut flour and remained stable over a 12-month period. E coli and salmonella were absent from all lots of flour. Yeast, mold, total aerobic bacteria, and aflatoxin were within established US Pharmacopeia guidelines on all lots tested and remained within the criteria over a 12-month period. CONCLUSIONS: Peanut flour used as a drug product contains the major peanut allergens and has low levels of potentially harmful microbes. Both these parameters remain stable over a 12-month period.
BACKGROUND: Oral immunotherapy (OIT) is an investigational therapeutic approach for the treatment of food allergies. Characterization of the drug product used in oral immunotherapy trials for peanutallergy has not been reported. OBJECTIVE: To quantify relative amounts of the major peanut allergens and microbial load present in peanut flour used in OIT trials and assess whether these parameters change over a 12-month period. We also anticipate that this report will serve as a guide for investigators seeking to conduct OIT trials under Food and Drug Administration-approved Investigational New Drug applications. METHODS: Densitometric scanning of Ara h 1 and Ara h 2 resolved on SDS-PAGE gels was used to assess allergen content in peanut flour extracts. Microbial testing was conducted on peanut flour under US Pharmacopeia guidelines for the presence of Escherichia coli, salmonella, yeast, mold, and total aerobic bacteria. In addition, aflatoxin was quantified in peanut flour. Reported results were obtained from 4 unique lots of peanut flour. RESULTS: Relative amounts of the major peanut allergens were similar between different lots of peanut flour and remained stable over a 12-month period. E coli and salmonella were absent from all lots of flour. Yeast, mold, total aerobic bacteria, and aflatoxin were within established US Pharmacopeia guidelines on all lots tested and remained within the criteria over a 12-month period. CONCLUSIONS:Peanut flour used as a drug product contains the major peanut allergens and has low levels of potentially harmful microbes. Both these parameters remain stable over a 12-month period.
Authors: Corinne A Keet; Pamela A Frischmeyer-Guerrerio; Ananth Thyagarajan; John T Schroeder; Robert G Hamilton; Stephen Boden; Pamela Steele; Sarah Driggers; A Wesley Burks; Robert A Wood Journal: J Allergy Clin Immunol Date: 2011-11-30 Impact factor: 10.793
Authors: James T Li; David I Bernstein; Moises A Calderon; Thomas B Casale; Linda Cox; Giovanni Passalacqua; Oliver Pfaar; Nikolaos G Papadopoulos Journal: J Allergy Clin Immunol Date: 2015-09-12 Impact factor: 10.793
Authors: A Wesley Burks; Stacie M Jones; Robert A Wood; David M Fleischer; Scott H Sicherer; Robert W Lindblad; Donald Stablein; Alice K Henning; Brian P Vickery; Andrew H Liu; Amy M Scurlock; Wayne G Shreffler; Marshall Plaut; Hugh A Sampson Journal: N Engl J Med Date: 2012-07-19 Impact factor: 91.245
Authors: Xiaolei Shi; Rishu Guo; Brittany L White; Adrienne Yancey; Timothy H Sanders; Jack P Davis; A Wesley Burks; Michael Kulis Journal: Int Arch Allergy Immunol Date: 2013-07-31 Impact factor: 2.749
Authors: Justin M Skripak; Scott D Nash; Hannah Rowley; Nga H Brereton; Susan Oh; Robert G Hamilton; Elizabeth C Matsui; A Wesley Burks; Robert A Wood Journal: J Allergy Clin Immunol Date: 2008-10-25 Impact factor: 10.793
Authors: Stacie M Jones; Laurent Pons; Joseph L Roberts; Amy M Scurlock; Tamara T Perry; Mike Kulis; Wayne G Shreffler; Pamela Steele; Karen A Henry; Margaret Adair; James M Francis; Stephen Durham; Brian P Vickery; Xiaoping Zhong; A Wesley Burks Journal: J Allergy Clin Immunol Date: 2009-07-03 Impact factor: 10.793
Authors: S R Prickett; A L Voskamp; T Phan; A Dacumos-Hill; S I Mannering; J M Rolland; R E O'Hehir Journal: Clin Exp Allergy Date: 2013-06 Impact factor: 5.018
Authors: Stacie M Jones; Edwin H Kim; Kari C Nadeau; Anna Nowak-Wegrzyn; Robert A Wood; Hugh A Sampson; Amy M Scurlock; Sharon Chinthrajah; Julie Wang; Robert D Pesek; Sayantani B Sindher; Mike Kulis; Jacqueline Johnson; Katharine Spain; Denise C Babineau; Hyunsook Chin; Joy Laurienzo-Panza; Rachel Yan; David Larson; Tielin Qin; Don Whitehouse; Michelle L Sever; Srinath Sanda; Marshall Plaut; Lisa M Wheatley; A Wesley Burks Journal: Lancet Date: 2022-01-22 Impact factor: 202.731
Authors: Stef J Koppelman; Mieke Smits; Monic Tomassen; Govardus A H de Jong; Joe Baumert; Steve L Taylor; Renger Witkamp; Robert Jan Veldman; Raymond Pieters; Harry Wichers Journal: Nutrients Date: 2018-09-11 Impact factor: 5.717
Authors: Evan S Dellon; Rishu Guo; Sarah J McGee; Deanna K Hamilton; Emily Nicolai; Jacquelyn Covington; Susan E Moist; Ashley Arrington; Benjamin L Wright; A Wesley Burks; Brian P Vickery; Michael Kulis Journal: Clin Transl Gastroenterol Date: 2019-12 Impact factor: 4.488
Authors: Wenshu He; Can Baysal; Maria Lobato Gómez; Xin Huang; Derry Alvarez; Changfu Zhu; Victoria Armario-Najera; Aamaya Blanco Perera; Pedro Cerda Bennaser; Andrea Saba-Mayoral; Guillermo Sobrino-Mengual; Ashwin Vargheese; Rita Abranches; Isabel Alexandra Abreu; Shanmugaraj Balamurugan; Ralph Bock; Johannes F Buyel; Nicolau B da Cunha; Henry Daniell; Roland Faller; André Folgado; Iyappan Gowtham; Suvi T Häkkinen; Shashi Kumar; Ramalingam Sathish Kumar; Cristiano Lacorte; George P Lomonossoff; Ines M Luís; Julian K-C Ma; Karen A McDonald; Andre Murad; Somen Nandi; Barry O'Keef; Subramanian Parthiban; Mathew J Paul; Daniel Ponndorf; Elibio Rech; Julio C M Rodrigues; Stephanie Ruf; Stefan Schillberg; Jennifer Schwestka; Priya S Shah; Rahul Singh; Eva Stoger; Richard M Twyman; Inchakalody P Varghese; Giovanni R Vianna; Gina Webster; Ruud H P Wilbers; Paul Christou; Kirsi-Marja Oksman-Caldentey; Teresa Capell Journal: Plant Biotechnol J Date: 2021-07-19 Impact factor: 13.263